Seer to Participate in the TD Cowen 46th Annual Health Care Conference

Seer, Inc. (Nasdaq: SEER), renowned for its innovative contributions to the field of deep proteomics, has announced its participation in the TD Cowen 46th Annual Health Care Conference set to take place in Boston, MA. On March 4th, 2026, at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time, Seer’s management will engage in a fireside chat aimed at sharing insights about the company's pioneering initiatives and advancements in proteomic technologies. Interested parties can access a live webcast of the event via the Investor section of Seer’s website—investor.seer.bio—and an archived replay will be made available post-conference for those unable to attend.

Seer, Inc. is at the forefront of proteomics, providing high-quality insights that combine speed, precision, and reproducibility, which traditional proteomic methods often struggle to achieve. The company’s Proteograph Product Suite employs a unique integration of engineered nanoparticles, automated instrumentation, and sophisticated analytical software, addressing the limitations of conventional proteomic approaches. These include issues such as inconsistent data quality, limited throughput, and excessive complexity that have hindered research advancements in the field.

Seer's focus on delivering scalable solutions is transforming the landscape of biological insights and research applications. Importantly, all of Seer’s products are designated for research use only and are not intended for diagnostic purposes. For more information regarding Seer's innovative proteomic strategies and leadership in the market, stakeholders are encouraged to visit the official website at www.seer.bio. Media inquiries can be directed to Patrick Schmidt at pr@seer.bio, while investor-related questions should be sent to investor@seer.bio.

As Seer, Inc. (Nasdaq: SEER) makes its way to the TD Cowen 46th Annual Health Care Conference, investors should closely monitor their participation for potential market impacts. Seer, a leader in proteomics, continues to demonstrate a unique value proposition with its Proteograph Product Suite. By integrating proprietary nanoparticles, streamlined automation, and advanced analytical software, Seer addresses critical gaps in traditional proteomic methodologies, which could redefine industry standards.

Upcoming events like this conference typically serve as platforms for companies to communicate progress, strategic direction, and new developments. Seer’s management will partake in a fireside chat, providing an opportunity for investors and analysts to gain deeper insights into the company's operations, innovations, and future prospects. Given Seer's commitment to delivering scalable and reproducible biological insights, stakeholders should glean how recent advancements may enhance market positioning and revenue growth.

Investors should note the current landscape of the biotechnology sector, where innovative and scalable solutions are highly coveted. With Seer poised to capture a larger share of the proteomics market, any disclosure about partnerships, clinical applications, or upcoming product launches during the conference could catalyze stock momentum.

Furthermore, the fact that Seer’s offerings are limited to research applications—rather than diagnostic procedures—positions them well within the growing emphasis on research spend in biotech and pharmaceuticals. Long-term investments should consider these factors alongside Seer’s recent performance metrics, market share, and competitive positioning.

In conclusion, watching Seer's narrative at the TD Cowen conference could reveal essential information that influences investor sentiment and market performance. As Seer continues to innovate within the proteomics domain, it presents a compelling case for investment, provided stakeholders monitor developments closely post-conference.